공시 • Apr 18
Marvel Biosciences Corp. announced that it has received CAD 0.5 million in funding On April 17, 2026, Marvel Biosciences Corp closed the transaction. 공시 • Apr 17
Marvel Biosciences Corp. and Marvel Biotechnology Inc Identify Liquid Formulations for Neurodevelopmental Disorders Marvel Biosciences Corp., and its wholly-owned subsidiary, Marvel Biotechnology Inc. announced it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204. This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children and adolescents with neurodevelopmental disorders, many of whom have difficulty swallowing pills or rely on feeding tubes, making standard solid oral dosage forms difficult or impractical to administer. The research focused on identifying a prototypic formulation that would ideally possess: Well accepted clinic ready excipients; A high concentration/low volume dosing solution; A simple, economic manufacturing process; Long term stability at room temperature; High oral bioavailability. Both formulations achieved higher drug levels of MB-204 in the blood of mice than our standard liquid-based formulation, which was used successfully in our depression and autism pre-clinical studies. We actually achieved 79 and 91% oral bioavailability (F%), which not only gives us a high degree of confidence that we should get meaningful drug exposures in patients in our Phase I trial, but also builds additional intellectual property around MB-204. The identification of a pediatric-friendly liquid formulation is another milestone in Marvel’s development pathway and expands MB-204's accessibility, particularly for its target patient populations. These advancements support accelerated regulatory engagement and clinical readiness, while additional formulation filings are expected to strengthen the Company’s intellectual property portfolio around novel delivery methods. Collectively, this progress Marvel’s transition into a more execution-focused phase, with a clear pathway toward clinical validation and key value inflection points. New Risk • Apr 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.5m free cash flow). Negative equity (-CA$3.9m). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$8.82m market cap, or US$6.40m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change). New Risk • Mar 08
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 41% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.1m free cash flow). Negative equity (-CA$3.7m). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$8.82m market cap, or US$6.49m). Recent Insider Transactions Derivative • Mar 01
Executive Chairman & CEO exercised options to buy CA$563k worth of stock. On the 24th of February, J. Matheson exercised options to buy 4m shares at a strike price of around CA$0.12, costing a total of CA$500k. This transaction amounted to 143% of their direct individual holding at the time of the trade. Since June 2025, Matheson's direct individual holding has increased from 1.62m shares to 7.07m. Company insiders have collectively bought CA$628k more than they sold, via options and on-market transactions, in the last 12 months. 공시 • Dec 08
Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026 Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026. Board Change • Dec 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. Independent Director Babak Pedram was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. New Risk • Nov 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.2m free cash flow). Negative equity (-CA$4.0m). Revenue is less than US$1m. Market cap is less than US$10m (CA$8.41m market cap, or US$6.02m). Minor Risk Shareholders have been diluted in the past year (30% increase in shares outstanding). New Risk • Jun 20
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 33% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$2.9m). Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$6.35m market cap, or US$4.63m). Minor Risk Share price has been volatile over the past 3 months (17% average weekly change). New Risk • May 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$3.5m). Revenue is less than US$1m. Market cap is less than US$10m (CA$3.58m market cap, or US$2.59m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). 공시 • May 13
Marvel Biosciences Corp. announced that it has received CAD 1.01875 million in funding On May 12, 2025. Marvel Biosciences Corp. has closed the transaction. It has issued 8,150,000 units at a price of CAD 0.125 per Unit for aggregate gross proceeds of CAD 1,018,750. 공시 • Mar 29
Marvel Biosciences Corp. announced that it expects to receive CAD 1.5 million in funding Marvel Biosciences Corp. announces a non-brokered private placement of up to 12,000,000 units at a price of CAD 0.125 per unit for gross proceeds of CAD 1,500,000 on March 28, 2025. Each Unit will be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.175 per share. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offering 공시 • Jan 08
Marvel Biosciences Corp. announced that it expects to receive CAD 2.5 million in funding Marvel Biosciences Corp. announced a non-brokered private placement that it will issue up to 16,666,667 common shares of the company at a price of CAD 0.15 per common share for the gross proceeds of up to CAD 2,500,000.05 on January 7, 2025. The closing of the offering may occur in one or more tranches, the first of which is expected to close on or about February 14, 2025. The closing of the offering is subject to the receipt of all regulatory approvals, including the approval of the TSX Venture Exchange, and will occur within 45 days from the date hereof. The securities offered under the listed issuer financing exemption will not be subject to a hold period, pursuant to applicable Canadian securities laws. New Risk • Nov 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.2m free cash flow). Negative equity (-CA$2.8m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$7.39m market cap, or US$5.27m). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). 공시 • Nov 25
Marvel Biosciences Corp., Annual General Meeting, Jan 15, 2025 Marvel Biosciences Corp., Annual General Meeting, Jan 15, 2025. 공시 • Oct 13
Marvel Biosciences Shares Positive Results of Mb204 in the Oprm1 Model of Autism Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. shared promising results from a recent study on MB204. The research was conducted by Drs. Julie Le Merrer and Jerome Becker of the iBraiN Institute in Tours, France, to investigate the impact of MB204 in the Oprm1 mouse model of autism (widely used to study social behavior deficits). Marvel reported that just one hour after administering a single oral dose of MB204, the drug successfully reversed the social behaviour deficits typically seen in the model. Key Highlights: A high dose of MB204 (2.5 mg/kg) significantly restored social behaviour in all measured endpoints (p<0.0001). Improvements were seen in social interaction behaviours including, the number and duration of nose contacts, the number and duration of paw contacts, and time spent self-grooming, amongst others. A lower dose of MB204 (1 mg/kg) also reversed nearly all social behaviour deficits, showing a clear connection between dose and response. The higher dose of MB204 not only improved/restored social interactions in Oprm1 (autistic) mice, but even outperformed the social interactions of normal (non-autistic) mice on several endpoints, demonstrating MB204's potent pro- social effect. Currently, Drs. Le Merrer and Becker are now testing MB204 in another chronic Rett syndrome model (Mecp2) and are looking forward to seeing how it performs 'head-to-head' against the approved drug Trofinetide. New Risk • Sep 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$2.8m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$5.37m market cap, or US$3.96m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). New Risk • Jul 24
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$2.8m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$5.37m market cap, or US$3.90m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding). 공시 • May 17
Marvel Biosciences Corp. announced that it expects to receive CAD 1 million in funding Marvel Biosciences Corp. announced a non-brokered private placement of up to 10,000,000 units at a price of CAD 0.10 per unit for the gross proceeds of CAD 1,000,000 on May 16, 2024. Each Unit will be comprised of one common share and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.15 per share on the date that is two years from the date of the issuance. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offering payable in cash, plus finder’s warrants in an amount equal to up to 7% of the aggregate number of Units, with each Finder’s Warrant being exercisable to acquire one common share at a price of CAD 0.15 per share until two years following the issuance of the Finder’s Warrants. The Common Shares and the Warrants are subject to a hold period and resale restriction in Canada
that expires four months plus one day from the issuance of the Units and such other restrictions as imposed under applicable securities legislation. The Offering is subject to acceptance by the TSX Venture Exchange. New Risk • Mar 27
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.2m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-CA$2.5m). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$5.97m market cap, or US$4.40m). 공시 • Jan 21
Marvel Biosciences Corp. announced that it has received CAD 0.5 million in funding Marvel Biosciences Corp. announced a non-brokered private placement that it has issued unsecured convertible debentures for the gross proceeds of CAD 500,000 on January 19, 2024. The Debentures will mature 3 years following the date of issuance and will bear interest at a rate of twelve percent 12% per annum , payable annually in arrears. Interest may be repaid in cash or common shares, at the option of the company, based on the 20-day volume weighted average trading price of the common shares on the TSX Venture Exchange, calculated 3 days prior to the payment date, subject to the minimum price permitted by the TSX Venture Exchange. In the event that the volume weighted average trading price of the common shares on the TSX Venture Exchange is at least CAD 0.60 per share for a period of 10 consecutive trading days, at any time during the term of the debentures, the company shall have the right, at its discretion, to require the holder of the debentures to convert the outstanding principal amount into common shares at the conversion price. The company did not pay any commission, finder’s fee, or similar payment in connection with the offering. Pursuant to applicable Canadian securities laws, the debentures, as well as any underlying common shares to be issued upon conversion or exchange of these securities, are subject to a hold period of four months and one day. The Private Placement remains subject to the final approval of the TSX Venture Exchange. New Risk • Nov 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.3m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-CA$529k). Earnings have declined by 27% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$2.98m market cap, or US$2.19m). 공시 • Oct 28
Marvel Biosciences Corp., Annual General Meeting, Jan 09, 2024 Marvel Biosciences Corp., Annual General Meeting, Jan 09, 2024. 공시 • Aug 23
Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that it has successfully completed its 4-week good laboratory practice (GLP), FDA investigational new drug (IND), dose-ranging dog and rat studies for its lead drug candidate MB-204 paving the way for Phase 1 human trials to begin. MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration. New Risk • Jun 25
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$529k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.3m free cash flow). Negative equity (-CA$529k). Earnings have declined by 27% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$3.38m market cap, or US$2.56m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding). 공시 • Feb 16
Marvel Biosciences Corp. announced that it expects to receive CAD 1.5 million in funding Marvel Biosciences Corp. announced e a non-brokered private placement offering of unsecured convertible debentures for the gross proceeds of CAD 1,500,000 million on February 15, 2023. The Debentures will bear interest at the rate of eight percent (8%) per annum, payable annually and will mature on the date that is three years from the closing date. Interest may be repaid in cash or common shares, at the option of the company, based on the 20 day volume weighted average trading price of the common shares on the TSX Venture Exchange, calculated 3 days prior to the payment date, subject to the minimum price permitted by the TSX Venture Exchange. The Debentures will be convertible at the holder’s option into common shares of the company at a conversion price of CAD 0.12 per Common Share. The closing of the Private Placement is expected to occur on or about February 24, 2023, and is subject to regulatory approval, including approval of the TSX Venture Exchange. 공시 • Jan 07
Marvel Biosciences Completes A Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer's Disease and Depression Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that it has successfully completed a multi-kilogram scale run under current good manufacturing practices ("cGMP") of the active pharmaceutical ingredient (API) of the Company's lead asset MB-204 in partnership with Zhejiang Ausun Pharmaceutical Co. Ltd. (Ausun). The cGMP material obtained from this study will be utilized in the Company's upcoming Phase 1 clinical study. In the United States, it is estimated that 1 in 10 senior citizens over the age of 65 suffer from dementia. MB-204 is a novel solution to Alzheimer's that has similar properties to the FDA approved drug Istradefylline. MB-204 has, through the Company's studies, proven to be more effective and longer lasting, while offering higher reduction in depression and anxiety symptoms. MB-204 is a fluorinated derivative of the U.S. FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration. 공시 • Jan 04
Marvel Biosciences Corp. Successfully Completes Its Short Term Dose Ranging Study in Rats and Dogs for MB-204 Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announce that it has successfully completed its doseranging toxicology studies in rats and dogs, for its lead drug candidate MB204. These studies will assist in determining the doses for the INDenabling 4week GLP toxicology studies. MB204 is a fluorinated derivative of the U.S. FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration. 공시 • Dec 23
Marvel Biosciences Corp., Annual General Meeting, Feb 28, 2023 Marvel Biosciences Corp., Annual General Meeting, Feb 28, 2023. 공시 • Dec 13
Marvel Biosciences Corp. Initiates Its Final Fda-Required Experiment Prior to Initiating Human Trials for Its Lead Drug Candidate Mb-204 Marvel Biotechnology Inc. announces it has initiated its 10-day, dose-ranging toxicology study, using dogs, for its lead drug candidate MB-204. To date, the Company's MB-204 has shown positive and promising data addressing depression, anxiety as well as its potential benefit in protecting patient's vital organs while going through chemotherapy treatments. As the maximum tolerated single-dose studies have been completed, FDA guidelines for drug development next prescribe an approximately one-week multiple dosing study required to run the industry standard 4-week good lab practise (GLP) toxicology studies. The studies are all required by the FDA prior to entering FDA Phase I human trials. MB-204 is a fluorinated derivative of the U.S. FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration. 공시 • Dec 09
Marvel Biosciences Corp. and its Wholly Owned Subsidiary, Marvel Biotechnology Inc. Initiate its 7-Day Dose-Ranging, Toxicology Study, Using Rats, for its Lead Molecule MB-204 Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that it has initiated its 7-day dose-ranging, toxicology study, using rats, for its lead molecule MB-204. This is a vital step in preparation to initiate FDA Phase I human clinical trials. After completing the maximum tolerated single dose studies, the FDA requires another short study before entering the industry standard Good Lab Practice (GLP) toxicology studies. This study requires toxicology studies in two species, typically rats and dogs, to test the safety of new drugs before being able to run trials on humans. MB-204 is a fluorinated derivative of the U.S. FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving mood and concentration. 공시 • Nov 26
Marvel Biotechnology Inc. Announces Board Changes Marvel Biotechnology Inc. announced that, effective November 23, 2022, Mr. Babak Pedram has joined its Board of Directors. Mr. Pedram brings a vast degree of business, capital markets and scientific experience to Marvel's Boardof Directors. He is a seasoned capital market professional with over 15 years of experience as an investment banker, investor relations, and capital markets advisor to numerous biotech, healthcare and technology companies based in Canada, the United States and Sweden. Mr. Pedram is the founder and president of Virtus Advisory Group, a Toronto-based capital markets advisory firm. He is the co-founder of several successful start-ups, including two publicly traded companies listed on the Toronto Stock Exchange. Mr. Pedram has both Bachelor's and Master's of Science degrees from Queen's University. Marvel also wishes to announce the resignation of Mr. Jeremy Fehr as a Director of the Company, effective November 23, 2022. Marvel thanks Mr. Fehr for his outstanding service to the Company and wishes him all the best in his future endeavors. 공시 • Nov 23
Marvel Biosciences Corp. Lead Drug Candidate Mb-204 Demonstrates A 400% Increase in the Survival Rate of Animals Treated with A High Dose of the Cancer Treatment Cis-Platinum Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announce that in a recent study done by the Company, its lead drug candidate MB- 204 demonstrated a 400% increase in the survival rate of animals being treated by high doses of chemotherapy treatment, cis-platinum. Cis-platinum is commonly used for a wide range of cancers and is the most powerful chemotherapeutic treatment available today. Unfortunately, it has multiple potentially- catastrophic side effects including kidney and nerve damage, cognitive dysfunction and hearing loss. The risk of nephrotoxicity in patients taking cis-platinum is between 20% and 35% and leads to death, in the case of acute kidney injury (AKI) patients, forcing clinicians to carefully dose and monitor kidney health. In some cases cis-platinum treatment for cancer has to be terminated early without achieving the desired outcome. David Blum, a key member of Marvel's scientific advisory board, recently published data showing inhibiting the adenosine A2a receptor, using the approved drug Istradefylline, reduces kidney and nerve damage in cis- platinum treated animals. It was also previously reported that inhibiting the A2a receptor prevented cognitive dysfunction as well. Marvel's MB-204 directly targets the A2a receptor and blocks its activity. 공시 • Nov 16
Marvel Biosciences Lead Drug Candidate Mb-204 Demonstrated Superior Anti-Anxiety Activity over FDA-Approved Istradefylline in Head-To-Head Pre-Clinical Studies Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that in a pre-clinical test for anxiety, its lead drug candidate MB-204, a fluorinated derivative of Istradefylline, out-performed Istradefylline in a head-to-head pre- clinical and in depressive and anti-anxiety studies. Istradefylline is the only US FDA approved A2a receptor antagonist currently approved to treat Parkinson's disease. Using the well-established elevated plus maze pre-clinical model for anxiety, and the same doses of MB-204 as compared to Istradefylline (7.5 mg/kg) resulted in: Longer times spent in the open arms, especially in the first minute, which indicates a larger anti-anxiety effect Engaged in more risky behaviour than Istradefylline, as measured by head dipping behaviours again suggesting less anxiety Did not trigger excessive locomotive activity whereas Istradefylline did promote excessive locomotive activity Promoted ultrasonic vocalizations (USVs), whereas Istradefylline did not evoke any USVs which is indicative of social communication. Board Change • Nov 16
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. President, CEO & Executive Chairman Rod Matheson is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 공시 • Nov 08
Marvel Biosciences Corp. Lead Drug Candidate Mb-204 Successfully Targets Brain Receptor Important for Alzheimer's Disease and Depression Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that in a pre-clinical mouse study conducted by the Company, its lead drug candidate MB-204 successfully entered the brain and occupied its target, the adenosine A2a receptor. The adenosine A2a receptor has been validated by numerous scientific studies that it plays a significant role in various pathologies such as Alzheimer's Disease and depression. MB-204 is a fluorinated derivative of the U.S. FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration. 공시 • Nov 03
Marvel Biosciences Corp. and Its Wholly Owned Subsidiary, Marvel Biotechnology Inc. Successfully Completes Large-Scale Engineering Run of Novel Solid Amorphous Dispersion (Sad) Formulation of Mb-204 Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced it has successfully completed a large-scale engineering run of its novel solid amorphous dispersion (SAD) formulation of MB-204 by Zhejiang Ausun Pharmaceutical Co. Ltd. ("Ausun"). The engineering run material will be utilized to support the ongoing toxicology studies of MB-204 being conducted by Pharmaron Inc. The engineering run is a key step forward to manufacturing the Company's lead product at a large scale for FDA Phase I human trials. An engineering run is a trial run of a small batchsample demonstrating the manufacturing process and resolving any potential issues before entering formal cGMP documentation and activities. The Company previously reported a highly significant increase in drug exposures in pre-clinical testing using the SAD formulation. This formulation involves coating MB-204 in a special FDA approved sugar-like polymer (similar to starch for example). This novel formulation could potentially reduce the amount of drug needed for human dosing, thereby improving the economics for Marvel. MB-204 is a fluorinated derivative of the U.S. FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration. 공시 • Oct 28
Marvel Biosciences Advances Closer to Human Trials After the Completion of Second Maximum Tolerated Dose Study, Critical Milestone Towards FDA Clinical Studies Marvel Biosciences Inc. announced it has completed its maximum tolerated dose (MTD) toxicology study in dogs for its product MB-204, further validating the Company's lead drug candidate low toxicity characteristic. MTD toxicology studies define the high dose of a drug or therapy that does not cause unacceptable side effects or toxicity. The purpose of the MTD study is to determine safe starting doses for first in-human (FIH) clinical trials. Marvel's unique formulation increases bioavailability and absorption rate of the drug by the body. As a result, the dogs in the tests were able to successfully be exposed to the drug on a high dosage of MB-204 without adverse effects. The proven low toxicity of the MB-204 provides the Company with a great degree of confidence to enter human trials and begin the process of getting MB-204 approved by the FDA. MB-204 is the Company's lead compound and is a novel fluorinated form of Istradefylline (FDA approved anti- Parkinson's disease drug) and is a blood brain barrier permeable adenosine A2a receptor antagonist. Marvel is developing MB-204 for the treatment of depression and Alzheimer's Disease, as well NASH associated liver fibrosis. 공시 • Oct 18
Marvel Biosciences Corp. Completes Its Maximum Tolerated Dose Toxicology Study for Its Product MB-204 Marvel Biosciences Inc. announced it has completed its maximum tolerated dose (MTD) toxicology study for its product MB-204, validating its low toxicity. MB-204 is the Company's lead compound and is a novel fluorinated form of Istradefylline (FDA approved anti- Parkinson's disease drug) and is a blood brain barrier permeable adenosine A2a receptor antagonist. Marvel is developing MB-204 for the treatment of depression and Alzheimer's Disease, as well NASH associated liver fibrosis. MTD toxicology studies define the high dose of a drug or therapy that does not cause unacceptable side effects or toxicity. The purpose of the MTD study is to determine safe starting doses for first in-human (FIH) clinical trials. The Company used a unique formulation to increase oral bioavailability, which drove high absorption of the drug by the body. As a result, the rats that were used in the study were exposed to very high acute dosage of MB-204 and their bodies were able to tolerate this high dosage. The low toxicity of the Company's lead product is a positive indication of what to expect in future clinical studies and the Company's ability to move its key drug candidate successfully through the FDA approval process. 공시 • Aug 10
Marvel Biosciences Corp. announced that it has received CAD 0.72 million in funding On August 9, 2022, Marvel Biosciences Corp. closed the transaction. The company has issued 2,700,000 units for gross proceeds of CAD 270,000 in its final tranche. The company has issued 7,200,000 units for total gross proceeds of CAD 7,200,000 in the transaction. The transaction included participation from directors and officers of the company for 850,000 units and gross proceeds of CAD 85,000 in the transaction. The company has paid finders' fee of CAD 26,000 in cash to Research Capital Corporation, Raymond James Ltd. and Canaccord Genuity Corp. 공시 • Jul 22
Marvel Announces Identification of A Novel Formulation of Its Mb-204 Asset Marvel Biosciences Inc. announced that its rapid formulation screening program with Catalent Inc., has identified a novel formulation of its lead asset MB-204. The formulation involves producing a solid amorphous dispersion of MB-204 using a simple, FDA approved excipient that has improved drug exposures by at least a factor of 20-fold. Improving oral bioavailability results in reduced amounts of drug needed to achieve a target dose which could in turn reduce costs and/or side effects. 공시 • Jun 22
Marvel Biosciences Corp. announced that it expects to receive CAD 0.7 million in funding Marvel Biosciences Corp. announced a proposed non-brokered private placement of 7,000,000 units at a price of CAD 0.10 per unit for gross proceeds of CAD 700,000 on June 21, 2022. Each unit will be comprised of one common share in the capital of the company and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at an exercise price of CAD 0.15 on or before the date that is the earlier of one year from the date of closing or in the event that the volume weighted average trading price of the common shares of the Company on the TSX Venture Exchange is at least CAD 0.20 for a minimum of 10 consecutive trading days, the company may, at its sole discretion, issue a news release announcing that the exercise period has been reduced to thirty days following the date of the issuance of such news release. The Company may pay a cash finders fee equal up to 8% of the gross proceeds to the company made by investors in the offering introduced to the Company by the finder. The transaction is subject to acceptance by the TSX Venture Exchange. Board Change • Apr 27
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Executive Chairman & CEO Rod Matheson is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 공시 • Feb 02
Marvel Biosciences Corp. Announces Change of Chief Financial Officer Marvel Biosciences Corp. announce the appointment of Harry Nijjar, CPA, CMA, as Chief Financial Officer of the Company, effective February 1, 2022, replacing Preston Maddin who left the Company effective January 31, 2022. Mr. Nijjar joined Malaspina Consultants Inc. in 2011 and is currently a Managing Director. Malaspina Consultants Inc. has been engaged by the Corporation to provide CFO, operational accounting and strategic financial advisory services. Mr. Nijjar has worked extensively with public companies across various industries, helping them navigate the regulatory and financial reporting environment. 공시 • Dec 19
Marvel Biosciences Completes Manufacturing Engineering Run of Lead Asset MB-204 Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced it has successfully completed a multi-kilogram engineering run of its lead MB-204 asset by Zhejiang Ausun Pharmaceutical Co. Ltd. ("Ausun"). The engineering run material will be used for its ongoing toxicology studies of MB-204 being conducted by Pharmaron Inc. ("Pharmaron"). Pharmaron's whose principal offices are in Louisville, Kentucky, is a public company listed on the Hong Kong and Shenzhen Stock exchanges and is a premier research and development service provider for the life sciences industry. MB-204, is a fluorinated derivative developed by Marvel of the US-FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world, whose consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration. 공시 • Nov 24
Marvel Biosciences Lead Asset MB-204 Show 47% Reduction In Liver Fibrosis And Active Indications In Multiple Pre-Clinical Models Of Nash Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that it has found its lead asset, MB-204 was active in two different pre-clinical models of non-alcoholic steatohepatitis ("NASH") using fibrosis and the non-alcoholic fatty liver disease activity score (NAS score) endpoints that are analogous to the known approvable NASH endpoints with the FDA. These early indications highlight a promising trajectory for MB-204 as a prospective treatment for NASH disease. NASH is a global disease that affects a significant portion of the population with a global market representing over $20B USD. The major concern for physicians and their patients is the development of liver fibrosis which can result in cirrhosis and liver cancer. Currently, there are no approved treatments for NASH, and very few treatments in development are focused on reduction in fibrosis. The most advanced active candidate specifically targeting fibrosis is Cenicriviroc which is currently in Phase 3 clinical trials. The Company studied its lead adenosine A2a receptor antagonist MB-204 in two pre-clinical NASH models and concluded the following: In the first model, focusing on the NAS Score, 6-week old STAM® mice (SMC, Japan) were treated with MB-204 (10 mg/kg), once daily per oral for 3 weeks. A 1.4 point drop in the NAS score (p<0.01) was observed, with a particularly strong effect seen on hepatocyte ballooning (p<0.0001) compared to vehicle; In the second model, focusing on fibrosis, 30-week old pre-aged NASH mice (Taconic) were treated once daily per oral for approximately 3 weeks with MB-204 (10mg/kg) or Cenicriviroc (30 mg/kg), the leading anti-fibrotic treatment for NASH in Phase 3 clinical trials. A 47% reduction in fibrosis was observed comparing control and MB-204, and MB-204 was significantly better (p<0.05) compared to Cenicriviroc in this experiment. Board Change • Sep 08
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). CEO & Director Rod Matheson is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. 